Abarelix

Abarelix is a synthetic decapeptide that acts as a direct gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists (such as leuprolide and triptorelin) that initially stimulate and then suppress the pituitary, GnRH antagonists like abarelix immediately and competitively block GnRH receptors, resulting in rapid suppression of LH, FSH, and consequently testosterone production without any initial surge or flare effect.

Approved by the FDA in 2003 as Plenaxis, abarelix was the first GnRH antagonist approved for the treatment of advanced symptomatic prostate cancer in patients who could not tolerate other hormonal therapies or who required immediate testosterone suppression. The absence of testosterone flare is clinically significant because the flare can cause temporary disease worsening, including exacerbation of bone pain, urinary obstruction, and spinal cord compression in patients with advanced disease.

Abarelix achieves castrate testosterone levels rapidly, typically within one week of the first injection, compared to 2-4 weeks for GnRH agonists. This rapid onset is particularly valuable in patients with impending spinal cord compression or bladder outlet obstruction where any delay or temporary worsening could have serious consequences.

However, abarelix's commercial success was limited by concerns about systemic allergic reactions, including immediate-onset anaphylactoid reactions reported in approximately 1.1% of patients. This safety concern led to the drug being available only through a restricted distribution program in the United States and ultimately to its withdrawal from the US market, though it remains available in some European countries. The development of degarelix, a next-generation GnRH antagonist with a more favorable safety profile, has largely supplanted abarelix in clinical practice.